Hemostasis & Tissue Sealing Agents Market Competitive Market Share & Forecast, 2017-2025

 

Hemostasis & Tissue Sealing Agents Market

Hemostasis is a physiological process that preserves blood fluidity by limiting blood loss from the body. Clots form during hemostasis as a result of the natural coagulation cascade being activated. However, excessive blood loss that results from major surgery or trauma cannot be stopped by the body's normal healing mechanisms. Hemostats and tissue sealing agents help in such circumstances by reducing blood loss and promoting wound healing. In order to reduce the risk associated with excessive bleeding during surgical procedures, hemostats and tissue sealing agents are being used more frequently.

Additionally, excessive bleeding can lead to postoperative complications such as drawn-out surgeries and insufficient blood levels in the body. Blood loss may be the cause of up to 31% of fatalities in trauma and catastrophic accident patients in the United States, according to In-Patient Epidemiology, a statistical study conducted by the Department of Surgery, Division of Acute Care and Trauma Surgery, New York University, in 2012. Therefore, avoiding such occurrences is crucial for the success of surgical procedures and for the good health of patients. Topical hemostats, such as mechanical hemostats, active hemostats, and Flowable hemostats—solutions applied topically directly to the bleeding site—along with natural and artificial tissue sealants serve as an adjunct to the body's normal hemostasis process and are used locally to control bleeding.

The Global Hemostasis & Tissue Sealing Agents Market Was Valued At US$ 3,236.2 Million In 2017 And Is Expected To Witness A Robust CAGR Of 8.1% Over The Forecast Period (2017–2025).

The market for hemostasis and tissue sealing agents is anticipated to grow significantly as a result of factors like the rising number of surgeries and auto accidents. For instance, according to the Health and Social Care Information Centre (HSCIC), surgery accounted for 4.7 million admissions across various sectors in 2013–14, making it one of the most significant treatments provided by NHS care in the U.K. The data also suggests that, between 2004 and 2014, there was a 27% increase in surgical procedures. The Centers for Disease Control and Prevention (CDC) estimate that about 200,000 Americans died in 2014 as a result of trauma injuries. A significant contributor to the rise in traumatic sports injuries is the frequency of increasing road accidents.

Over 50% of those harmed in auto accidents in 2016 were hospitalised and underwent trauma surgery, according to the World Health Organization. Due to the larger incisions made on the patient's body during trauma surgeries and other common procedures like hernia repair, orthopaedic, open heart and cardiovascular surgery, and neurosurgery that result in significant blood loss, hemostats are also used in these procedures. A total of 427,181 procedures were reported for joint replacement surgeries in 2016, according to the American Joint Replacement Registry's (AJRR) annual report. However, it is anticipated that the lack of favourable reimbursement policies for hemostats' failure to control blood loss as well as the rising cost of surgical procedures will restrain market expansion.

Top Companies involved are- Cryolife, Inc. Baxter International, Inc., Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc., Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc, and others.

Comments

Popular posts from this blog

Security Robot Market is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Surveillance

The Ever-Evolving Landscape of the Scottish Whisky Market during the Forecast Period 2019-2027

Monochloroacetic Acid (MCAA) Market Is Estimated To Witness High Growth Owing To Increasing Demand for Surfactants and Herbicides